Graphical Abstract Keywords Metabolic dysfunction-associated steatotic liver disease, Glucagon-like peptide-1 receptor agonist, Clinical trial, Treatment, Metabolic dysfunction-associated steatohepatitis, Fibrosis Introduction Nonalcoholic fatty liver disease has been used to describe hepatic steatosis without significant alcohol intake
La terapia debe evaluarse peridicamente para confirmar que los beneficios continan superando los riesgos
Incretin-pathway research has advanced from single-receptor agonism toward multi-receptor strategies that interrogate energy balance, glucose handling, hepatic lipid flux, and satiety circuits in a coordinated fashion
Conclusion and Expectations Many scientific investigations have focused on the impact and mechanisms of therapies based on insulin-stimulating hormones, such as GLP-1
Daher liegt es nahe, dass die Substanz bei der Fettverbrennung hilft